182P: Intracranial Response to Nivolumab in NSCLC Patients With Untreated or Progressing CNS Metastases

Journal of Thoracic Oncology - United States
doi 10.1016/s1556-0864(16)30292-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Osimertinib Treats CNS Metastases in NSCLC

Cancer Discovery
Oncology
2018English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Elemene Treatment for NSCLC With Multiple CNS Metastases: A Case Report and Literature Review

OncoTargets and Therapy
OncologyPharmacology
2018English

Cannabis Impacts Tumor Response Rate to Nivolumab in Patients With Advanced Malignancies

Oncologist
Cancer ResearchMedicineOncology
2019English

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

JAMA Oncology
Cancer ResearchOncology
2019English

P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Development of CNS Metastases and Survival in Patients With Inflammatory Breast Cancer

Cancer
Cancer ResearchOncology
2018English

MA08.11 Early Safety Data of a Phase I/Ii Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients With NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P023 Factors Associated With Administration of Subsequent Cytotoxic Chemotherapy After Nivolumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy